Olema Director Tied To BVF Partners Resigns From Board, With BVF Holding 9.8%

Dr. Gorjan Hrustanovic left the board and two committees effective October 14, the 13D amendment says, with no disagreement cited.

Share
Olema Director Tied To BVF Partners Resigns From Board, With BVF Holding 9.8%

Dr. Gorjan Hrustanovic resigned from Olema Pharmaceuticals' board effective October 14, according to a Schedule 13D amendment filed Friday by BVF Partners, which reports a 9.8% stake in the company. He also left the board's Compensation Committee and its Science and Technology Committee.

What the amendment says

The filing, Amendment No. 4, says the resignation was not the result of any disagreement with Olema on any matter relating to its operations, policies or practices. Item 4, the section covering the purpose of the holding, added only the resignation.

Hrustanovic is himself a reporting person. He is listed with 183,645 shares, or 0.2% of class, all issuable on stock options exercisable within 60 days. The options were awarded to him for no consideration for his board service. Under an agreement with BVF Partners, he must pass on to the firm any economic benefit from selling shares issued on exercise.

The filing also says none of the reporting persons traded Olema securities in the past sixty days.

The size of the BVF stake

BVF Partners, as investment manager, reports 8,939,731 shares, or 9.8% of the shares outstanding. That count includes pre-funded warrants, which are warrants exercisable for one share each at $0.0001 per share. Mark Lampert, BVF Inc. and BVF Partners are each shown with the same figure.

The warrant total is larger than what can be counted. The reporting persons and one managed account hold pre-funded warrants for 6,373,040 shares, but a 9.99% ownership blocker limits exercise to 3,643,838 shares.

The percentages rest on 87,497,607 shares outstanding as of August 6, 2026, taken from Olema's 10-Q filed August 10, 2026. Among the funds, Biotechnology Value Fund L.P. holds 5,946,981 shares (6.6%) and Biotechnology Value Fund II LP holds 2,356,800 (2.7%).

The stock

Olema shares closed at $6.58 on Friday, down about 4% on the session, for a market value of $601 million.

The filing's Item 4 carries no new demands or plans from BVF; its only change is the departure of Hrustanovic from the board and his two committees.

Sources

More on Olema Pharmaceuticals

All Olema Pharmaceuticals (OLMA) coverage →